The Quantellect read.As of Nov 19, 2026, 3 active firms cover Nuvectis Pharma Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $33.00 to $39.00, so the covering firms are broadly aligned. The average target of $36.00 sits 78% above the current $20.26. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.28 next quarter toward $-1.70 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$36.00
+77.7% upside
Average target across 2 active firms as of Nov 19, 2026 vs $20.26 current
Highest Target$39.00
Average Target$36.00
Lowest Target$33.00
Detailed analyst forecasts for NVCT
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate NVCT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
NVCT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.28
Range $-0.34 – $-0.22 · 2 analysts · +8% YoY
Next period, 2 analysts expect Nuvectis Pharma Inc to earn $-0.28 a share (range $-0.34 – $-0.22), versus $-0.26 a year earlier. Full-year consensus is $-2.03, growing to $-1.70 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Nuvectis Pharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NVCT.
#1
PS
Pete Stavropoulos
Cantor Fitzgerald · Rank #300
Buy
No targeton NVCT
Overall win rate
35%
+ Follow
#2
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$39.00+92.5% to target
Overall win rate
34%
+ Follow
#3
NR
Naz Rahman
Maxim Group · Rank #578
Buy
$17.00-16.1% to target
Overall win rate
27%
+ Follow
#4
Jonathan Aschoff
Roth MKM · Rank #588
Buy
$33.00+62.9% to target
Overall win rate
28%
+ Follow
#5
YJ
Yale Jen
Laidlaw & Co.
Buy
$19.00-6.2% to target
Coverage
—
+ Follow
NVCT stock forecast FAQ
What is NVCT's average 12-month price target?+
The 2 active firms with a live target average $36.00 for Nuvectis Pharma Inc over the next 12 months, ranging from a $39.00 high to a $33.00 low, as of Nov 19, 2026.
Is NVCT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for NVCT?+
The Street-high target is $39.00 (HC Wainwright & Co.), and the Street-low is $33.00 (Roth Capital). The average of all 2 active-firm targets is $36.00.
How many active Wall Street firms cover NVCT?+
3 active firms have a recognized rating on Nuvectis Pharma Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering NVCT?+
Among analysts who currently cover NVCT, Pete Stavropoulos of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #300). Their current call is Buy.
What is Nuvectis Pharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.28 per share (range $-0.34 – $-0.22) across 2 analysts. Full-year EPS is projected at $-2.03, rising to $-1.70 the following year.
How much revenue is Nuvectis Pharma Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading NVCT lately?+
As of Nov 19, 2026, 3 of 3 active firms rate NVCT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NVCT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.